Cyramza ® (ramucirumab)

För fullständig produktresumé för Cyramza® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Cyramza® (ramucirumab): Antikroppsberoende cellmedierad cytotoxicitet

Cyramza (ramucirumab) framkallade inte respons i antikroppsberoende cellmedierade cytotoxicitetstester (ADCC) i de undersökta cellinjerna.



Detailed Information

The activity of ramucirumab was investigated against a variety of VEGFR-2 expressing target cells in order to evaluate the potential of ramucirumab to mediate ADCC activity.

Two different assays, both using ramucirumab and PMBC, were utilized.

  1. ADCC receptor gene assay

  2. Classical cytotoxicity assay

Ramucirumab was negative in both ADCC assays in vitro, and it is considered unlikely that ramucirumab will display ADCC activity in vivo.1,2

References

1. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) Assessment Report on Cyramza, 2017 (31 Oct 2017, date last accessed). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002829/WC500180726.pdf.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

ADCC = antibody-dependent cell-mediated cytotoxicity

PBMC = peripheral blood mononuclear cell 

VEGFR-2 = vascular endothelial growth factor receptor 2

Datum fӧr senaste ӧversyn 2017 M09 20

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss